margetuximab (MGAH 22) - MacroGenics
Margetuximab: "In this study, shorter margetuximab infusion times starting from C2 appear to be well tolerated"; Breast cancer (Macrogenics) - Dec 12, 2019 - SABCS 2019: "94% of IRRs occurred during C1 with the 120-minute infusion" 
P3 data
http://ir.macrogenics.com/static-files/87d88181-eea7-4875-b9d8-86a05cd0a6f1
 
Dec 12, 2019
 
 
217ff153-3369-4746-97b9-65b0308b876b.jpg

e4f07c24-86c8-4044-a1fd-d6003857f571.jpg

efbf1377-3f24-4075-83b2-9b7e6dd94827.jpg